SCHEMBL2354635

SCHEMBL2354635

O=C(O)c1ccc2cc(-c3ccc(CCc4ccccc4)cc3)ccc2c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLAU P00749 1/20 0.53
RARB P10826 5/20 0.51
RARG P13631 3/20 0.51
RARA P10276 2/20 0.51
PDE4A P27815 1/20 0.50
PDE4B Q07343 1/20 0.50
PDE4C Q08493 1/20 0.50
PDE4D Q08499 1/20 0.50
SRD5A2 P31213 1/20 0.50
BCL2 P10415 1/20 0.50
TOP2A P11388 1/20 0.49
TOP2B Q02880 1/20 0.49
NR1H4 Q96RI1 1/20 0.49
GRIN2D O15399 1/20 0.49
GRIN2A Q12879 1/20 0.49
GRIN2B Q13224 1/20 0.49
GRIN2C Q14957 1/20 0.49
PTGES O14684 1/20 0.48
ALOX5 P09917 1/20 0.48
NR4A2 P43354 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2357478 0.92 PLAU (0.55) PLAURARBRARGRARAPDE4A
SCHEMBL2349393 0.90 PTGES (0.58) RARBRARGRARASRD5A2BCL2
SCHEMBL2362674 0.89 PTGES (0.56) PLAURARBRARASRD5A2BCL2
SCHEMBL12243165 0.88 MAPT (0.51) PLAURARBRARGRARABCL2
SCHEMBL2310774 0.86 KMO (0.62) RARBRARGRARA
SCHEMBL30526912 0.84 RARB (0.62) RARBRARGRARA
SCHEMBL29049592 0.84 RARB (0.62) RARBRARGRARA
SCHEMBL2350638 0.84 CYP19A1 (0.56) PLAUTOP2ATOP2BNR1H4
SCHEMBL12243162 0.83 MAPT (0.54) PLAUBCL2TOP2ATOP2B
SCHEMBL5047765 0.82 RARB (0.60) RARBRARGRARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8921309-B2 Lipopeptide compounds and their use UNIQUEST PTY LIMITED (AU) 2014-12-30 US disclosed
EP-2350119-B1 LIPOPEPTIDE COMPOUNDS AND THEIR USE UNIQUEST PTY LTD (AU) 2014-10-29 EP disclosed
US-20110224129-A1 Lipopeptide Compounds and Their Use MERLION PHARMACEUTICALS PTE LTD (SG) 2011-09-15 US disclosed
EP-2350119-A1 LIPOPEPTIDE COMPOUNDS AND THEIR USE Merlion Pharmaceuticals Pte Ltd. (SG) 2011-08-03 EP disclosed
WO-2010062264-A1 LIPOPEPTIDE COMPOUNDS AND THEIR USE MERLION PHARMACEUTICALS PTE LTD (SG) 2010-06-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110224129-A1 Lipopeptide Compounds and Their Use VIP, LTA, CLPTM1 PLAU 1267/4885RARB 2792/4885RARG 2742/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.